Genetic abnormalities with prognostic significance
| Favorable genetic lesions |
| t(8;21 )(q22;q22)/RUNX1-RUNX1T1 |
| inv(16)(p13.1;q22)/t(16;16)(p13.1;q22)/CBFB-MYH11 |
| NPM1 mutation with or without FLT3-ITD |
| CEBPA mutation with or without FLT3-ITD |
| Unfavorable genetic lesions |
| inv(16)(p13.3q24.3)/CBFA2T3-GLIS2 |
| t(10;11)(p12;q23)/KMT2A-AF10 |
| t(10;11)(p11.2;q23)/KMT2A-ABI1 |
| t(6;11)(q27;q23)/KMT2A-MLLT4 |
| t(4;11)(q21;q23.3)/KMT2A-MLLT2 |
| t(11;12)(p15;p13)/NUP98-KDM5A |
| t(7;11)(p15.4;p15)/NUP98-HOXA9 |
| t(5;11)(q35;p15)/NUP98-NSD1 |
| t(6;9)(p23;q34)/DEK-NUP214 |
| t(8;16)(p11;p13)/KAT6A-CREBBP |
| t(16;21)(q24;q22)/RUNX1-CBFA2T3 |
| t(7;12)(q36;p13)/ETV6-HLXB |
| t(3;21)(26.2;q22)/RUNX1-MECOM |
| t(16;21)(p11.2;q22.2)/ FUS-ERG |
| FLT3-ITD without CEPBA or NPM1 mutation |
| inv(3)(q21.3q26.2)/t(3;3)(q21.3q26.2)/RPN1-MECOM |
| t(3;5)(q25;q34)/NPM1-MLF1 |
| t(10;11)(p12.3;q14.2)/PICALM-MLLT10 |
| −7, −5, 5q− |
| Favorable genetic lesions |
| t(8;21 )(q22;q22)/RUNX1-RUNX1T1 |
| inv(16)(p13.1;q22)/t(16;16)(p13.1;q22)/CBFB-MYH11 |
| NPM1 mutation with or without FLT3-ITD |
| CEBPA mutation with or without FLT3-ITD |
| Unfavorable genetic lesions |
| inv(16)(p13.3q24.3)/CBFA2T3-GLIS2 |
| t(10;11)(p12;q23)/KMT2A-AF10 |
| t(10;11)(p11.2;q23)/KMT2A-ABI1 |
| t(6;11)(q27;q23)/KMT2A-MLLT4 |
| t(4;11)(q21;q23.3)/KMT2A-MLLT2 |
| t(11;12)(p15;p13)/NUP98-KDM5A |
| t(7;11)(p15.4;p15)/NUP98-HOXA9 |
| t(5;11)(q35;p15)/NUP98-NSD1 |
| t(6;9)(p23;q34)/DEK-NUP214 |
| t(8;16)(p11;p13)/KAT6A-CREBBP |
| t(16;21)(q24;q22)/RUNX1-CBFA2T3 |
| t(7;12)(q36;p13)/ETV6-HLXB |
| t(3;21)(26.2;q22)/RUNX1-MECOM |
| t(16;21)(p11.2;q22.2)/ FUS-ERG |
| FLT3-ITD without CEPBA or NPM1 mutation |
| inv(3)(q21.3q26.2)/t(3;3)(q21.3q26.2)/RPN1-MECOM |
| t(3;5)(q25;q34)/NPM1-MLF1 |
| t(10;11)(p12.3;q14.2)/PICALM-MLLT10 |
| −7, −5, 5q− |
ITD, internal tandem duplication.